Login / Signup

Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.

Catia MarzoliniSara GibbonsJoep J van OosterhoutSaye Khoo
Published in: Clinical pharmacokinetics (2021)
Keyphrases
  • mycobacterium tuberculosis
  • adverse drug
  • drug induced
  • pulmonary tuberculosis
  • risk assessment
  • climate change